$OMIC
Singular Genomics Systems Inc

2024 Q2 Form 10-Q Financial Statement

#000095017024059533 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $737.0K $442.0K
YoY Change 45.94% -48.78%
Cost Of Revenue $915.0K $861.0K
YoY Change 53.27% 6.69%
Gross Profit -$178.0K -$419.0K
YoY Change 93.48% -848.21%
Gross Profit Margin -24.15% -94.8%
Selling, General & Admin $11.90M $14.94M
YoY Change -20.08% 13.11%
% of Gross Profit
Research & Development $10.73M $11.49M
YoY Change -15.02% -6.02%
% of Gross Profit
Depreciation & Amortization $1.067M $1.019M
YoY Change 22.08% 28.5%
% of Gross Profit
Operating Expenses $22.63M $26.43M
YoY Change -17.76% 3.91%
Operating Profit -$22.80M -$26.85M
YoY Change -17.39% 5.79%
Interest Expense $286.0K $284.0K
YoY Change 5.93% 9.65%
% of Operating Profit
Other Income/Expense, Net $1.550M $1.824M
YoY Change -23.46% 4.53%
Pretax Income -$21.25M -$25.02M
YoY Change -16.91% 5.89%
Income Tax
% Of Pretax Income
Net Earnings -$21.25M -$25.02M
YoY Change -16.91% 5.89%
Net Earnings / Revenue -2883.85% -5661.54%
Basic Earnings Per Share -$8.57 -$0.34
Diluted Earnings Per Share -$8.57 -$0.34
COMMON SHARES
Basic Shares Outstanding 74.09M 73.93M
Diluted Shares Outstanding 2.481M 73.93M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $133.4M $151.1M
YoY Change -35.62% -33.3%
Cash & Equivalents $30.12M $24.11M
Short-Term Investments $103.3M $127.0M
Other Short-Term Assets $2.424M $2.155M
YoY Change -41.32% -21.69%
Inventory $12.44M $13.08M
Prepaid Expenses $1.539M $1.116M
Receivables $440.0K $137.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $148.7M $166.5M
YoY Change -34.12% -32.46%
LONG-TERM ASSETS
Property, Plant & Equipment $13.25M $13.85M
YoY Change 15.34% 23.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.078M $1.078M
YoY Change -11.86% -6.42%
Total Long-Term Assets $71.31M $72.63M
YoY Change 22.34% 23.11%
TOTAL ASSETS
Total Short-Term Assets $148.7M $166.5M
Total Long-Term Assets $71.31M $72.63M
Total Assets $220.0M $239.1M
YoY Change -22.53% -21.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.498M $2.012M
YoY Change -24.11% 1.77%
Accrued Expenses $4.049M $3.265M
YoY Change -2.36% -2.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.938M $2.625M
YoY Change
Total Short-Term Liabilities $16.95M $16.08M
YoY Change 21.48% 28.73%
LONG-TERM LIABILITIES
Long-Term Debt $6.355M $7.627M
YoY Change -37.3% -24.51%
Other Long-Term Liabilities $624.0K $605.0K
YoY Change -26.93% -39.38%
Total Long-Term Liabilities $6.979M $8.232M
YoY Change -36.5% -25.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.95M $16.08M
Total Long-Term Liabilities $6.979M $8.232M
Total Liabilities $82.30M $82.40M
YoY Change 25.47% 26.5%
SHAREHOLDERS EQUITY
Retained Earnings -$383.9M -$362.6M
YoY Change 31.47% 36.11%
Common Stock $0.00 $7.000K
YoY Change -100.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $137.7M $156.7M
YoY Change
Total Liabilities & Shareholders Equity $220.0M $239.1M
YoY Change -22.53% -21.73%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$21.25M -$25.02M
YoY Change -16.91% 5.89%
Depreciation, Depletion And Amortization $1.067M $1.019M
YoY Change 22.08% 28.5%
Cash From Operating Activities -$18.04M -$23.70M
YoY Change -9.8% 32.17%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $25.00K
YoY Change -99.67% -84.57%
Acquisitions
YoY Change
Other Investing Activities $23.97M $31.60M
YoY Change -168.9% -56.77%
Cash From Investing Activities $23.96M $31.58M
YoY Change -168.3% -56.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K 0.000
YoY Change -87.06% -100.0%
NET CHANGE
Cash From Operating Activities -18.04M -23.70M
Cash From Investing Activities 23.96M 31.58M
Cash From Financing Activities 80.00K 0.000
Net Change In Cash 6.006M 7.876M
YoY Change -111.03% -85.68%
FREE CASH FLOW
Cash From Operating Activities -$18.04M -$23.70M
Capital Expenditures $1.000K $25.00K
Free Cash Flow -$18.04M -$23.73M
YoY Change -11.16% 31.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001850906
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40443
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Singular Genomics Systems, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2948451
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3010 Science Park Road
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
333-7830
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
OMIC
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74092970
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24109000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16233000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
126629000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
157708000
CY2024Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
137000
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
565000
CY2024Q1 us-gaap Inventory Net
InventoryNet
13081000
CY2023Q4 us-gaap Inventory Net
InventoryNet
13572000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2519000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4150000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
166475000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
192228000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57094000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57797000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13854000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13692000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
600000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
600000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1078000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1150000
CY2024Q1 us-gaap Assets
Assets
239101000
CY2023Q4 us-gaap Assets
Assets
265467000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2012000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2587000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3265000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6079000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7822000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7764000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2980000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1857000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16079000
CY2023Q1 us-gaap Interest Expense
InterestExpense
259000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18287000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58092000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58623000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7627000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8901000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
605000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
650000
CY2024Q1 us-gaap Liabilities
Liabilities
82403000
CY2023Q4 us-gaap Liabilities
Liabilities
86461000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74067366
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74067366
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73823161
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73823161
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
519361000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
516439000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-51000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
155000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-362619000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337595000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
156698000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179006000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
239101000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
265467000
CY2024Q1 us-gaap Revenues
Revenues
442000
CY2023Q1 us-gaap Revenues
Revenues
863000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
861000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
807000
CY2024Q1 us-gaap Gross Profit
GrossProfit
-419000
CY2023Q1 us-gaap Gross Profit
GrossProfit
56000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11494000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12230000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14935000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13204000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
26429000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
25434000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26848000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25378000
CY2024Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
2108000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
2004000
CY2024Q1 us-gaap Interest Expense
InterestExpense
284000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1824000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1745000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-25024000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23633000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73925966
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73925966
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71926412
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71926412
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-25024000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23633000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-206000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
446000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25230000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23187000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179006000
CY2024Q1 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
26000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2896000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-206000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-25024000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
156698000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2023Q1 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
97000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3081000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
446000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23633000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240325000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-25024000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-23633000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2896000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3081000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
703000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1024000
CY2024Q1 us-gaap Depreciation
Depreciation
1019000
CY2023Q1 us-gaap Depreciation
Depreciation
793000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
39000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
38000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
751000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1327000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-428000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-899000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1320000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-831000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1651000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1031000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-72000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-28000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1781000
CY2024Q1 omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
-2706000
CY2023Q1 omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
-1447000
CY2024Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-190000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
92000
CY2024Q1 omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-473000
CY2023Q1 omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-276000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-19000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
87000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23703000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17934000
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19184000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7018000
CY2024Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
50619000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
72144000
CY2024Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
169000
CY2023Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
7981000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
162000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31579000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72945000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
CY2024Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7876000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55017000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16833000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24709000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130994000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
246000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
216000
CY2024Q1 omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
1180000
CY2023Q1 omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
1009000
CY2024Q1 omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
594000
CY2023Q1 omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
562000
CY2024Q1 omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
59000
CY2023Q1 omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
217000
CY2024Q1 omic Vesting Of Restricted Stock
VestingOfRestrictedStock
26000
CY2023Q1 omic Vesting Of Restricted Stock
VestingOfRestrictedStock
97000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24109000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16233000
CY2024Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
97000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-362600000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337600000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
150700000
CY2024Q1 omic Period Of Operations Sufficient To Fund
PeriodOfOperationsSufficientToFund
P12M
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
600000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
600000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24709000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16833000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
126680000
CY2024Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-51000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
126629000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
157553000
CY2023Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
155000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
157708000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
126629000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
157540000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
168000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
126629000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
157708000
CY2024Q1 us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue from sales of its products, which currently consist of the G4 instrument, related consumable flow cell kits and services. Revenue from instrument sales is recognized generally upon customer acceptance. Revenue from consumables sales is recognized generally upon shipment to the customer. Revenue from services, which are primarily comprised of assurance-type services, is recognized over the applicable service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recorded net of discounts and sales taxes. The Company invoices its customers for instruments generally upon acceptance, for consumables generally on delivery, and for services generally in advance of the service period. Invoice terms are generally net 30 days. Cash received from customers in advance of revenue recognition is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company regularly enters into contracts that include a combination of products and services, which are distinct within the context of the contract and are accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. Until the Company has sufficient volume of historical sales data for each performance obligation, the Company determines the standalone selling price using observable prices when available and with consideration of current market conditions, which is primarily based on prices set by management, adjusted for applicable discounts. The Company then recognizes revenue for each performance obligation as that performance obligations is satisfied, as discussed above.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into instrument arrangements with certain customers, under which the Company provides the G4 instrument at no cost to the customer, other than shipping, and the customer pays for consumables at list price, or at list price plus a mark-up, as consumables are ordered, shipped and invoiced. Revenue is recognized as consumables are shipped to the customer and disclosed within consumables revenue below. The G4 instrument provided to the customer is recorded on the balance sheet as property and equipment and disclosed as instruments at customer sites under Note 6 to these financial statements. Depreciation expense for these instruments is included in cost of revenue. Revenue associated with any lease elements of these arrangements was not material during the three months ended March 31, 2024 and 2023.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue for G4 instruments and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of revenue for G4 consumables and services. Contract liabilities, which consists of deferred revenue, as of March 31, 2024 and December 31, 2023 were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this balance was classified as current. Deferred revenue represents the value of performance obligations that have been invoiced but for which revenue has not yet been earned.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> all of the Company’s revenue was generated within the United States. During the period, the Company generated approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue from its top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers.</span></p>
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
200000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
300000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
200000
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company invests its cash equivalents in highly rated money market funds. The Company’s marketable securities consist of short-term investments in a variety of interest-bearing instruments, which have included U.S. government and agency securities, high-grade U.S. corporate bonds and asset-backed securities. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits with financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”). During the periods presented, the Company has not experienced any losses on its cash, restricted cash, cash equivalents or marketable securities.</span></p>
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
10596000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
11627000
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
2046000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1276000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
439000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
669000
CY2024Q1 us-gaap Inventory Net
InventoryNet
13081000
CY2023Q4 us-gaap Inventory Net
InventoryNet
13572000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1116000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1672000
CY2024Q1 us-gaap Interest Receivable
InterestReceivable
1039000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
1019000
CY2024Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
364000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1459000
CY2024Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2519000
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4150000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22893000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21713000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9039000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8021000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13854000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13692000
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1982000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5229000
CY2024Q1 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
278000
CY2023Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
264000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
361000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
178000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
644000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
408000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3265000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6079000
CY2024Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-09-01
CY2024Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0075
CY2024Q1 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.04
CY2024Q1 omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.04
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
200000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
400000
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
248000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
287000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10252000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10213000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
2625000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1312000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7627000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8901000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
62000
CY2024Q1 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
100000
CY2024Q1 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
18129
CY2023Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
34384
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2122000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
5886000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4510000
CY2024Q1 omic Long Term Debt Maturities Repayments Of Principal Including Interest Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalIncludingInterestPayments
12518000
CY2024Q1 omic Interest And Final Payment Fee
InterestAndFinalPaymentFee
2018000
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
248000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10252000
CY2024Q1 omic Accrued Payment Related To Milestone
AccruedPaymentRelatedToMilestone
500000
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
1100000
CY2024Q1 us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
2900000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
800000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2100000
CY2023Q1 us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
3000000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
900000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2100000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6097000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5716000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8607000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8580000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8837000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
79058000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
116895000
CY2024Q1 omic Operating Lease Future Minimum Payments Less Discount
OperatingLeaseFutureMinimumPaymentsLessDiscount
-50981000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
65914000
CY2024Q1 omic Less Current Portion
LessCurrentPortion
7822000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58092000
CY2022Q1 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
0.0001
CY2022Q1 omic Percentage Of Amended Shares Of Common Stock
PercentageOfAmendedSharesOfCommonStock
0.049
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The number of shares of common stock reserved for issuance under the 2021 Plan is increased automatically on the first day of each fiscal year, commencing in 2022 and ending in 2031, by a number equal to the lesser of: (i) 5% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company’s Board of Directors.
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24377381
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11751749
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.18
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6045163
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.55
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
641110
CY2024Q1 omic Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Forfeiture Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageForfeiturePrice
4.01
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11110639
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.2
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
127000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6453705
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.49
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2896000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3081000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16700000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7848
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0365
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19298556
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16071575

Files In Submission

Name View Source Status
0000950170-24-059533-index-headers.html Edgar Link pending
0000950170-24-059533-index.html Edgar Link pending
0000950170-24-059533.txt Edgar Link pending
0000950170-24-059533-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omic-20240331.htm Edgar Link pending
omic-20240331.xsd Edgar Link pending
omic-ex31_1.htm Edgar Link pending
omic-ex31_2.htm Edgar Link pending
omic-ex32_1.htm Edgar Link pending
omic-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
omic-20240331_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable